Department of Cardiology, Nottingham University Hospitals NHS Trust, , Nottingham, UK.
Heart. 2014 Jun;100(11):842-7. doi: 10.1136/heartjnl-2013-304976. Epub 2014 Apr 7.
Syncope is a cause of significant morbidity in sick sinus syndrome (SSS) which may not be resolved with permanent pacemaker therapy. We aimed to determine the incidence, predictors and prognostic implication of syncope in paced patients with SSS.
We studied 1415 patients (mean age 72.9 years, SD 11.1) with SSS who were randomised in the DANPACE study to either rate-responsive single chamber pacing (n=707) or rate-responsive dual chamber pacing (n=708). Main outcome measures were patient-reported syncope after pacemaker implantation and mortality.
Mean follow-up was 5.4 years (SD 2.6). A total of 247 (17.5%) patients experienced syncope after pacemaker implantation (135 (19%) from the rate-responsive single chamber pacing group, and 112 (15.8%) from the rate-responsive dual chamber pacing group. Predictors of syncope post pacemaker implantation included: age 0-39 years (HR 2.9, 95% CI 1.4 to 6.3, p=0.01; reference range 60-79 years), age ≥80 years (HR 1.4, 95% CI 1.0 to 1.8, p=0.03), syncope prior to pacemaker implant (HR 1.8, 95% CI 1.4 to 2.3, p<0.001), previous myocardial infarction (HR 1.5, 95% CI 1.1 to 2.1, p=0.03), heart failure (HR 1.4, 95% CI 1.0 to 1.9, p=0.046), and high Charlson comorbidity index (HR 1.6, 95% CI 1.1 to 2.2, p=0.01). Patients who experienced syncope post pacemaker implant had higher mortality compared with patients who did not (adjusted HR 1.6, 95% CI 1.3 to 2.1, p<0.001).
Syncope in paced patients with SSS is common, and is associated with higher mortality. The predictors identified in this study suggest a multifactorial aetiology of syncope.
晕厥是病窦综合征(SSS)患者发生严重发病率的原因,永久性起搏器治疗可能无法解决这一问题。本研究旨在确定在 SSS 起搏患者中晕厥的发生率、预测因素和预后意义。
我们研究了 1415 名 SSS 患者(平均年龄 72.9 岁,标准差 11.1),他们在 DANPACE 研究中被随机分为两组:反应性单腔起搏(n=707)或反应性双腔起搏(n=708)。主要观察指标为起搏器植入后患者报告的晕厥和死亡率。
平均随访时间为 5.4 年(标准差 2.6 年)。共有 247 名(17.5%)患者在起搏器植入后发生晕厥(反应性单腔起搏组 135 例[19%],反应性双腔起搏组 112 例[15.8%])。起搏器植入后发生晕厥的预测因素包括:年龄 0-39 岁(HR 2.9,95%CI 1.4-6.3,p=0.01;参考范围 60-79 岁),年龄≥80 岁(HR 1.4,95%CI 1.0-1.8,p=0.03),起搏器植入前晕厥(HR 1.8,95%CI 1.4-2.3,p<0.001),既往心肌梗死(HR 1.5,95%CI 1.1-2.1,p=0.03),心力衰竭(HR 1.4,95%CI 1.0-1.9,p=0.046)和高 Charlson 合并症指数(HR 1.6,95%CI 1.1-2.2,p=0.01)。与未发生晕厥的患者相比,发生晕厥的起搏器植入患者死亡率更高(调整后的 HR 1.6,95%CI 1.3-2.1,p<0.001)。
SSS 起搏患者晕厥很常见,且与更高的死亡率相关。本研究确定的预测因素提示晕厥具有多因素病因。